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Plasmodium falciparum, the primary cause of deaths
from malaria, is a purine auxotroph and relies on
hypoxanthine salvage from the host purine pool.
Purine starvation as an antimalarial target has been
validated by inhibition of purine nucleoside phos-
phorylase. Hypoxanthine depletion kills Plasmodium
falciparum in cell culture and in Aotus monkey
infections. Hypoxanthine-guanine-xanthine phos-
phoribosyltransferase (HGXPRT) from P. falciparum
is required for hypoxanthine salvage by forming ino-
sine 50-monophosphate, a branchpoint for all purine
nucleotide synthesis in the parasite. Here, we
present a class of HGXPRT inhibitors, the acyclic im-
mucillin phosphonates (AIPs), and cell permeable
AIP prodrugs. The AIPs are simple, potent, selective,
and biologically stable inhibitors. The AIP prodrugs
block proliferation of cultured parasites by inhibiting
the incorporation of hypoxanthine into the parasite
nucleotide pool and validates HGXPRT as a target
in malaria.
INTRODUCTION
Malaria is a major global health concern that is responsible for
greater than 200 million clinical cases and 800,000 deaths
each year (WHO, 2008). The vaccines formalaria currently in clin-
ical trials confer limited protection and resistance to artemisinin
and its derivatives has been detected in Southeast Asia (Bejon
et al., 2008; Noedl et al., 2008). These developments illustrate
the continued need to develop new antimalarial compounds
against novel targets.
Plasmodium falciparum lacks the enzymatic machinery to
synthesize purines de novo (Reyes et al., 1982). Additionally,
the parasite lacks adenosine kinase or adenine phosphoribosyl-
transferase activity and relies on the conversion of hypoxan-
thine to inosine 50-monophosphate by hypoxanthine-guanine-
xanthine phosphoribosyltransferase (PfHGXPRT) as its primary
source of purines (Cassera et al., 2008). Hypoxanthine depletionChemistry & Biology 19,through either xanthine oxidase-mediated degradation or purine
nucleoside phosphorylase (PNP) inhibition has been demon-
strated to kill parasites in cell culture (Berman and Human,
1991; Kicska et al., 2002b). Inhibition of both parasite and host
PNP kills P. falciparum in Aotus monkeys (Cassera et al., 2011).
The transition states of N-ribosyl transferases are usually
characterized by ribocation character and low bond order to
the purine ring and the attacking nucleophile. For example,
orotate phosphoribosyltransferases (Tao et al., 1996; Zhang
et al., 2009) and purine nucleoside phosphorylases (Kline and
Schramm, 1993, 1995) share these properties. HGXPRTs have
resisted transition state analysis because of kinetic commitment
factors. We proposed a transition state structure for PfHGXPRT
based on the assumption of ribocation character at the transition
state of this reaction (Figure 1A) (Li et al., 1999). Immucillin-H
50-phosphate (ImmHP) has been shown to be a 1 nM inhibitor
of PfHGXPRT (Li et al., 1999). However, phosphate monoesters
are incompatible with biological activity. The phosphate charges
make ImmHP impermeable to cells and the phosphate group is
vulnerable to the action of phosphomonoesterases. Keough
and colleagues demonstrated inhibition of PfHGXPRT by acyclic
nucleoside phosphonates (Keough et al., 2009). These
compounds replace the labile phosphate with a biologically
stable phosphonate.
In this work, we present what is to our knowledge a new class
of selective PfHGXPRT inhibitors, the acyclic immucillin phos-
phonates (AIPs). The AIPs attain the affinity of ImmHP for
PfHGXPRT while being biologically stable and synthetically
accessible. Prodrug analogs of AIPs are active against cultured
P. falciparum and inhibit hypoxanthine incorporation. The mech-
anism of inhibition has been revealed with crystal structures of
PfHGXPRT in complex with an AIP and magnesium pyrophos-
phate and with a substrate complex of hypoxanthine and
magnesium pyrophosphate.
RESULTS
Action of Immucillin-H 50-Phosphate
ImmHP is a 1 nM inhibitor of recombinant PfHGXPRT and human
HGPRT. However, ImmHP lacks activity against cultured
P. falciparum in the presence of hypoxanthine (data not shown).
We synthesized a prodrug of ImmHP to overcome the cell721–730, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 721
Figure 1. Proposed HGXPRT Transition State Structures and Transi-
tion State Analogs of PfHGXPRT
(A) Proposed transition state based on the transition states of enzymes
catalyzing similar reactions. Li et al. (1999) proposed this transition state for
HG(X)PRT with a protonated N7 and oxocarbenium ion formation at C10.
(B) Immucillin-H 50-phosphate was designed as a mimic of this proposed
transition state. The acyclic immucillin phosphonates (AIPs) 2 and 3 are
powerful and selective inhibitors of PfHGXPRT. The AIPsmaintain key features
of immucillin-H 50-phosphate including the 9-deazahypoxanthine nucleobase,
ribocationic nitrogen, and a phosphonate group.
(C) The inhibition constants for 2 and 3 with PfHGXPRT and human HGPRT.
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50-phosphate group (1 in Figure 2A). Compound 1 demonstrated
a 5.8 ± 1.2 mM half maximal inhibitory concentration (IC50) in
assays with parasites (Figure 2B). However, metabolic labeling722 Chemistry & Biology 19, 721–730, June 22, 2012 ª2012 Elsevierstudies of erythrocytes with 1 showed inhibition of inosine
conversion to hypoxanthine resulting from the dephosphoryla-
tion of 1 to immucillin-H, a powerful inhibitor of PNP (Figures
2C and 2D). Treatment of infected erythrocytes with 1 and anal-
ysis by ultra performance liquid chromatography (UPLC)/mass
spectrometry (MS)/MS revealed that 1 is permeable to cells,
but that cellular metabolism rapidly removes the 50-phosphate
to form immucillin-H (Table S1 available online), a potent inhibitor
of P. falciparum and human PNPs (Kicska et al., 2002a).
Acyclic Immucillin Phosphonates Are Selective and
Potent Inhibitors of PfHGXPRT
We identified two potent inhibitors of PfHGXPRT (Figure 1B).
Both compounds were designed to match the predicted transi-
tion state features of ImmHP, specifically the 9-deazahypoxan-
thine nucleobase, ribocationic nitrogen, and a phosphonate
group.
Both compounds 2 and 3 are competitive inhibitors of
PfHGXPRT with Ki values of 10.6 and 0.65 nM, respectively
(Figure 1C). When tested against human HGPRT compounds 2
and 3 displayed lower affinities of 4,940 and 385 nM. Thus,
compounds 2 and 3 are, respectively, 466- and 592-fold more
selective for the parasite enzyme than the human enzyme.
AIP Prodrugs Inhibit Proliferation of Plasmodium
falciparum in Culture by Inhibiting Hypoxanthine
Metabolism
The free phosphonate inhibitors showed no activity against
cultured parasites, consistent with a lack of membrane perme-
ability. Prodrug 4 (Figure 3A), the bis-pivalate of 2, inhibited the
growth of cultured parasites with an IC50 of 45 ± 6 mM (Figure 3B).
Metabolic labeling of erythrocytes with [3H]hypoxanthine in
the presence of 100 mM 4 revealed incorporation of radiolabel
into extracellular inosine and other intermediates and labeling
with [3H]inosine showed inhibition of inosine conversion to hypo-
xanthine (Figure 3C). UPLC/MS/MS analysis of infected erythro-
cytes treated with 100 and 200 mMof 4 for 30 min confirmed that
4 is processed to 2 in infected erythrocytes, causing an increase
in inosine concentration (Table S1). Hypoxanthine was not found
in treated or control samples, suggesting that HG(X)PRT activity
was unaffected. 2 inhibits human PNP with submicromolar
affinity (Table S2). The accumulation of extracellular inosine
from labeled erythrocytes indicates that 4 is permeable, but is
converted to 2 before crossing the parasite membranes. In the
erythrocyte, compound 2 inhibits PNP causing accumulation of
inosine. At higher concentrations, 4 also crosses the parasite
membranes, is activated and inhibits PfHGXPRT activity.
Compounds 5, 6, 7, and 8 are lysophospholipid mimics
intended to provide prodrug bioavailability (Figure 4) (Hostetler,
2009). The prodrugs were assayed to determine the IC50 values
against P. falciparum strain 3D7 (Figure 4B). Compounds 5, 6,
and 7 inhibited parasite growth in vitro with IC50 values of
2.5 ± 0.2, 1.9 ± 0.1, and 7.0 ± 0.1 mM, respectively. The IC50
values for compounds 5 and 6 were similar when tested against
chloroquine/mefloquine-resistant strain Dd2 (3.0 ± 0.1 and
2.3 ± 0.1 mM) or chloroquine/quinine resistant strain FVO
(2.9 ± 0.1 and 3.1 ± 0.1 mM). Compound 8 did not inhibit parasite
growth at concentrations up to 15 mM. Parasite killing by inhibi-
tion of PNP can be rescued by exogenous hypoxanthine, butLtd All rights reserved
Figure 2. A Prodrug of Immucillin-H 50-Phosphate Is Converted to Immucillin-H by Intracellular Activities
(A) The structure of immucillin-H 50-phosphate (ImmHP) bis-pivalate prodrug 1.
(B) Inhibition of cultured parasite growth by 1.
(C) Extracellular purine analysis of metabolic labeling with [3H]hypoxanthine in uninfected erythrocytes treated with 25 mM 1.
(D) The same experiment as in (C) but labeling with [3H]inosine. See also Table S1.
All error bars are representations of the SEM for a minimum of three replicate experiments.
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assays were conducted at a range of exogenous hypoxanthine
concentrations from 0 to 185 mM. The IC50 values showed no
significant variation with increasing concentrations of exoge-
nous hypoxanthine (all IC50 values between 2.2 and 2.4 mM
from 3 to 185 mM hypoxanthine). Thus the site of action is inhibi-
tion of PfHGXPRT (Figure 4C).
We further defined PfHGXPRT as the target of the AIP
prodrugs by metabolic studies. Incorporation of radiolabeled
hypoxanthine by uninfected erythrocytes was unchanged by
incubation with 10 mM of 5 (Figure 5A and Table 1). The label
was incorporated into the erythrocyte IMP and GMP pools with
smaller amounts appearing in GDP and GTP. The lack of incor-
poration into the adenine nucleotides is expected since human
erythrocytes lack adenylosuccinate synthase activity. The
effects of 5 on erythrocyte-free parasites consistently demon-
strated a modest reduction of incorporation of hypoxanthine
into the parasite nucleotide pool (Figure 5B and Table 1).
The strongest effects of AIP inhibitors on PfHGXPRT activity
were seen in infected erythrocytes. Compounds 5 and 6
decreased incorporation of radiolabeled hypoxanthine by 85%
(Figures 5C and S1A and Table 1) and caused the accumulation
of extracellular hypoxanthine (Figure 5D). Inhibition was similar
when 5 or 6 was present during incubation of parasites with
radiolabeled hypoxanthine or in preincubation experiments
where excess inhibitor was removed prior to the addition of
radiolabel. Inhibition of hypoxanthine uptake by 5 or 6 wasChemistry & Biology 19,stronger in infected erythrocytes than in isolated parasites.
Thus, erythrocytes play a role in activating the prodrug and/or
transporting it into the parasite.
Compound 7 is the monoester of 5 and showed similar
antiparasitic activity in IC50 assays (7.0 versus 2.5 mM from
Figure 4C). In metabolic labeling experiments, incubation of
infected erythrocytes with 15 mM 7 did not inhibit incorporation
of label into parasitic nucleotides (Figure S1B). Thus, the ethyl
phosphonate esters of 5 and 6 permit more effective inhibition
of PfHGXPRT than 7.
In time- and concentration-dependent inhibition experiments,
maximum inhibition of hypoxanthine uptake by 5 was complete
after thirty minutes of treatment and increased linearly with
concentrations of 5 between 0.5 and 5 mM (Figures 5E and 5F).
Structural Basis of Inhibitor Binding
Active Site of PfHGXPRT
PfHGXPRT forms a homotetramer in solution and each subunit
is folded into a single domain containing the PRTase-like fold.
Each subunit of the tetramer contains an active site, which can
be divided into four functional regions: the purine binding site,
the ribose binding site, 50-phosphate binding site and pyrophos-
phate/magnesium ion binding site (Figure 6). The purine-binding
site is formed primarily by hydrophobic residues, including
Tyr116, Ile146, Phe197, Val198, and Leu203 (Figure 6A). Two
charged residues in the purine-binding site, Asp146 and
Lys176, form hydrogen bonds to N7 and O6 of the purine moiety721–730, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 723
Figure 3. Acyclic Immucillin Phosphonate Prodrugs Must Avoid Activation in the Erythrocyte to Reach Parasite Targets
(A) The structure of AIP prodrug 4, the bis-pivalate compound prodrug of 2.
(B) Inhibition of parasite growth inhibition by 4.
(C) Extracellular purine analysis of metabolic labeling in uninfected erythrocytes treated with 100 mM 1 and [3H]hypoxanthine.
(D) The same experimental design as in (C) but labeling with [3H]inosine. See also Table S2.
All error bars are representations of the SEM for a minimum of three replicate experiments.
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and a water molecule, coordinated by a magnesium ion, form
hydrogen bonds to O6, N1, and N3 of the purine, respectively.
The ribose moiety interacts with magnesium pyrophosphate
complex and Asp145 (Figure 6B). The 50-phosphate binding
site is lined with the side-chain residues of Tyr116, Thr149, and
Thr152 and the amide nitrogens of Asp148, Thr149, Gly150,
and Thr152 (Figure 6C). Pyrophosphate is coordinated by the
side chains of Arg112, Arg210, the amide nitrogens of Lys77,
Gly78, Ser115, and Tyr116, and the magnesium ion (Figure 6B).
In the complex of ImmHP bound to PfHGXPRT (PDB ID: 1CJB),
the pyrophosphate ion pairs with two magnesium ions, both
octahedrally coordinated. One magnesium contacts O6 and
O7 of the pyrophosphate, the side chain of Asp204 and three
water molecules, while the second magnesium makes contact
with O2 and O4 of the pyrophosphate, the 20- and 30-hydroxyls
of ImmHP, and two water molecules. The first magnesium is
conserved in PfHGXPRT complexes with magnesium pyrophos-
phate and hypoxanthine and 3. The second magnesium is
absent in the complex with 3 and the first magnesium moves
closer to the phosphate-binding site in the complex with hypo-
xanthine (Figures 6B and S2A). The crystalographic data collec-
tion and refinement statistics for these two structures are con-
tained in Table 2.
Binding of 3 to PfHGXPRT
The acyclic amino alcohol phosphonate is arranged in the active
site of PfHGXPRT to place the cationic amino group near the
position occupied by the ribooxacarbenium ion in the proposed724 Chemistry & Biology 19, 721–730, June 22, 2012 ª2012 Elseviertransition state. This positions the cation close to the pyrophos-
phate (2.8 A˚; all distances are the average value from four mono-
mers) to create a favorable ion pair. Themethylene bridge linking
the amino cation and 9-deazahypoxanthine allows the deazapur-
ine to tilt 11 toward Phe197, a residue involved in aromatic ring
stacking (Figure 6D). The side chains of Asp148 (2.8 A˚) and Lys
(3.0 A˚), the amide and carbonyl of Val (3.1 and 2.7 A˚) and a struc-
tural water (2.6 A˚) coordinated by magnesium are in hydrogen
bonds with N7, O6, O6, N1, and N3 of the deazapurine of 3,
respectively. The atomic spacing between the amino cation
and the phosphonate group permits simultaneous favorable
inhibitor interactions with magnesium pyrophosphate and the
50-phosphate binding site. The 50-phosphonate of 3 interacts
with neighboring residues similarly to the phosphate of ImmHP
bound to PfHGXPRT (PDB ID: 1CJB). The side-chain residues
of Tyr116 (2.6 A˚), Thr149 (3.0 A˚), and Thr152 (2.6 A˚) and amides
of Asp148 (3.1 A˚), Thr149 (3.1 A˚), Gly150 (2.6 A˚), and Thr152
(2.9 A˚) are in hydrogen bond distance with the 50-phosphonate
while the 30-hydroxyl group of 3 forms a hydrogen bond with
the side chain of Asp145 (2.8 A˚). As 3 has only one hydroxyl group
compared to two in the ribosyl transition state, a water molecule
replaces the second hydroxyl group and forms a hydrogen bond
networkwith theO2 andO4 of pyrophosphate (2.6 and 2.7 A˚), the
30-hydroxyl group (2.9 A˚) and thecationic amine (2.9 A˚). Thesingle
magnesium is chelated by Asp204, three water molecules and
pyrophosphate. Pyrophosphate forms hydrogen bonds with the
side chains of Arg112 (2.9 A˚) and Arg210 (2.8 A˚) and the amides
of Gly78 (3.0 A˚), Lys77 (2.9 A˚), Ser115 (2.9 A˚), and Tyr116 (2.9 A˚).Ltd All rights reserved
Figure 4. Lysophospholipid Prodrugs Increase the Biological
Activity of the AIPs
The prodrug approach summarized by Hostetler (2009) was adapted to the
AIPs.
(A and B) Schematic representation of the AIP prodrugs and the IC50 values of
compounds 5–8.
(C) The biological IC50 values of 5 conducted at varying exogenous hypo-
xanthine concentrations.
All error bars are representations of the SEM for a minimum of three replicate
experiments.
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Chemistry & Biology 19,Binding of Hypoxanthine to PfHGXPRT
Hypoxanthine is the physiologic substrate of the PfHGXPRT
reaction. Ligands in the complex of PfHGXPRT with hypoxan-
thine and magnesium pyrophosphate interact with neighboring
residues similar to those for ImmHP binding, except for the
second magnesium (Figure S2A). Although the hypoxanthine
maintains a similar hydrogen bond network to bound
ImmHP, hypoxanthine tilts 5 toward Phe197, an aromatic ring
stacking interaction (Figure S2B). The second magnesium in the
PfHGXPRT complex with hypoxanthine moves toward the
50-phosphate binding site and is chelated to O1 of phosphate,
theO2of thepyrophosphateand fourwatermolecules.Twowater
molecules form hydrogen bonds to Glu144 and Asp145 indepen-
dently. Another water forms hydrogen bonds to N9 (2.6 A˚) andO1
of the pyrophosphate (2.9 A˚) and is positioned near the anomeric
carbon position expected for the transition state.
DISCUSSION
The transition state structures of other N-ribosyltransferases
(Kline and Schramm, 1993; Lewandowicz and Schramm, 2004;
Tao et al., 1996; Zhang et al., 2009) suggest a transition state
forPfHGXPRT that proceeds throughan ribocationwith aproton-
ated purine leaving group (Figure 1A) (Li et al., 1999). Immucillin-
H 50-phosphate resembles an early ribocationic transition state
for PfHGXPRT and is a nanomolar inhibitor of human and P. falci-
parumHG(X)PRTs. However, our results with 1 demonstrate that
the 50-phosphate group renders these potent inhibitors imper-
meable and/or makes them susceptible to phosphohydrolases
inside cells.
The phosphonate group of the AIPs mimics phosphate, but is
resistant to phosphohydrolases. Other phosphonates are in
clinical use as antivirals (Hostetler, 2009). Keough et al. synthe-
sized neutral 6-oxopurine acyclic nucleoside phosphonates
(ANPs) that were able to inhibit recombinant PfHGXPRT and
demonstrate antimalarial activity in in vitro culture (Keough
et al., 2009). These substrate analogs validate PfHGXPRT as
an in vitro antimalarial target. Our present advance is to develop
mimics of the transition state with intrinsic binding affinity orders
of magnitude tighter than neutral 6-oxopurine ANPs and with
higher specificity for parasite relative to the human enzyme.
Adapting aminocations into the inhibitor scaffold incorporates
transition state mimicry into these molecules. These molecules
are synthetically accessible and are more biologically stable
than ImmHP.Thecrystal structureofPfHGXPRTbound to ImmHP
and MgPPi shows the ribosyl-mimic 2
0- and 30-hydroxl groups of
ImmHP forming hydrogen bonds with Glu144, Asp145, and
awatermolecule coordinated bymagnesium. Loss of these inter-
actions might be expected to decrease the affinity of the AIPs;
however, this is not the case. The crystal structure of PfHGXPRT
bound to 3 and PPi shows a more favorable ionic bond between
PPi and the riboxocarbenium mimic. A water molecule replaces
the missing 20-hydroxyl group. These structural changes allow
the AIPs to adopt a favorable geometry in the catalytic site and
account for their high affinity in spite of their structural simplicity.
Additionally, thecationic reactioncenter of theAIPscreates favor-
able interactions that account for their significantly increased
affinity forPfHGXPRT as compared to the compounds presented
by Keough et al. with neutral reaction centers.721–730, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 725
Figure 5. Treatment of Infected Red Blood Cells with AIP Prodrugs Inhibits PfHGXPRT
Cells were metabolically labeled with [2,8-3H]hypoxanthine in the presence or absence of 10 mM 5 by incubation as in the methods. Purine incorporation was
quantitated by HPLC of (A) uninfected red blood cells (RBCs), (B) erythrocyte-free parasites, (C) parasites isolated from infected erythrocytes, (D) extracellular
purines from (C). The time (E) and concentration (F) dependence of label uptake were measured by liquid scintillation counting of spent media. The results are
summarized in Table 1. See also Figure S1.
All error bars are representations of the SEM for a minimum of three replicate experiments.
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best avoided since genetic defects causing loss of human
HGPRT activity leads to gouty arthritis (Kelley et al., 1968) and
complete loss of activity is the cause of Lesch-Nyhan syndrome,
a debilitating neurological disorder (Lesch and Nyhan, 1964;
Seegmiller et al., 1967). A selective inhibitor would avoid this
potential problem and would also avoid increases in serum
hypoxanthine levels by maintaining host HGPRT activity. Thus,
the 500-fold selectivity for PfHGXPRT demonstrated by 2
and 3 (Figure 1C) is beneficial.
Phosphonate groups have two negative charges at physio-
logic pH and are slowly taken up by human cells via endocytosis726 Chemistry & Biology 19, 721–730, June 22, 2012 ª2012 Elsevier(Connelly et al., 1993). Neither 2 nor 3 demonstrated activity
against cultured parasites, likely due to poor cell permeability.
To target PfHGXPRT, prodrugs of 2 or 3 must enter the erythro-
cyte and cross the parasitophorous vacuole and the parasite
plasma membranes. Compound 4, the bis-pivalate prodrug of
2, is able to cross into the erythrocyte. However, our data
suggest it is rapidly metabolized in the erythrocyte to form 2,
which inhibits erythrocyte PNP and is unable to permeate the
parasite cytoplasm.
A prodrug strategy that has been used to increase the efficacy
of the nucleoside phosphonates cidofovir and tenofovir was
more successful (Hostetler, 2009). The lysophospholipid tailLtd All rights reserved
Table 1. Metabolic Labeling Summary Showing the Percentage
Change in Incorporation of Radiolabel from [2, 8-3H]
Hypoxanthine into the Nucleotide Pool of P. falciparum Treated
with 10 mM of 5
Metabolite
Labeling Condition
RBCs Free Parasites Infected RBCs
Inosine 2 ± 5 38 ± 22 84 ± 8
Hypoxanthine 4 ± 1 40 ± 50 88 ± 3
IMP/GMP 6 ± 1 55 ± 26 88 ± 3
GDP/XMP 5 ± 2 44 ± 23 88 ± 4
GTP 7 ± 1 48 ± 19 75 ± 9
Adenosine/AMP 2 ± 1 37 ± 31 91 ± 3
ADP 9 ± 4 41 ± 20 79 ± 11
ATP 3 ± 3 42 ± 22 68 ± 22
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cells, phospholipase C (PLC) activity cleaves the prodrug re-
leasing the acyclic phosphonate inhibitor. This system is advan-
tageous for targeting P. falciparum since the Ca2+-dependent
PLC activity in erythrocytes displays a narrow substrate speci-
ficity for phosphorylated phosphoinositides and a PLC with
broad substrate specificity has been identified in P. falciparum
(Allan and Michell, 1978; Ferrell and Huestis, 1984; Hanada
et al., 2000, 2002). In lysophospholipid prodrugs of 2, phospho-
choline is replaced by an AIP, the sn2 hydroxyl is replaced with a
hydrogen and the sn3 ester linkage is replaced with an ether.
This creates prodrugs with activity against cultured
P. falciparum. Inhibition of hypoxanthine incorporation into para-
site nucleotide pools establishes PfHGXPRT as the target.
Following cellular activation, 2 is sequestered inside the para-
sites. In metabolic labeling experiments effective inhibition of
PfHGXPRT remained even when excess prodrug was removed.
The difference between the Ki of 2 (10 nM) and the IC50 of its pro-
drugs (3 mM) indicate that further optimization of the prodrug
scaffold is needed in the future.
Crystal structures of PfHGXPRT with 3 or hypoxanthine show
similar active sites to that of PfHGXPRT in complex with ImmHP
and also to HsHGPRT in complex with immucillin-GP (PDB ID:
1CJB and 1BZY) (Shi et al., 1999a, 1999b). In all structures the
catalytic loop of the hood domain is closed over the active site
and all residues in the active site overlap closely. The structural
similarity suggests the selectivity of the AIPs for PfHGXPRT arise
frommore favorable interactions of the ion pair between inhibitor
and bound magnesium pyrophosphate.
The structure of PfHGXPRT bound to 3, magnesium and pyro-
phosphate reveals the structural basis of the high affinity binding.
Structures of PfHGXPRT andHsHGPRT show similar positioning
of three elements, purine base, 50-phosphate and pyrophos-
phate, regardless of transition state mimicry. This geometry
establishes a six-bond distance between the nucleobase and
the phosphorous atom as the favored catalytic site spacing.
The acyclic structure of 3maintains this distance while estab-
lishing a 2.8 A˚ ion pair between the amino cation and O1 of
pyrophosphate. Crystal structures of PfHGXPRT with ImmHP
show a 3.2 A˚ ion pair. The stereochemistry of 3 places the amino
cation for favorable ion pair formation and tight binding, even
though some contacts of the ribosyl group are missing. TheChemistry & Biology 19,truncated structure of 3 allows an additional water molecule
into the active site, replacing the 20-hydroxyl of ImmHP in the
hydrogen bond network. The decreased ion-pair distance and
the structural water compensate energetically for the loss of
the 20-hydroxyl of ImmHP giving 3 an inhibition constant similar
to ImmHP.
A detailed kinetic mechanism of PfHGXPRT has not yet been
described, however the mechanisms of other HG(X)PRTs follow
an ordered sequential mechanism with PRPP binding first,
followed by purine base binding (Munagala et al., 1998; Wenck
et al., 2004; Xu et al., 1997). This mechanism predicts a dead-
end complex formed by the purine base and pyrophosphate.
The crystal structure of PfHGXPRT, hypoxanthine and magne-
sium is the first structural validation of this complex.
SIGNIFICANCE
The AIPs and their lysophospholipid prodrugs represent an
advance in the development of PfHGXPRT inhibitors as
potential antimalarial compounds. The AIPs are able to
match the affinity of ImmHP, are able to resist the action of
phosphohydrolases, are highly selective for the parasite
enzyme and show improved characteristics for synthesis.
The lysophospholipid prodrugs of the AIPs demonstrate
activity against cultured P. falciparum and robustly inhibit
the incorporation of hypoxanthine into the parasite nucleo-
tide pool. This evidence extends the work of Keough et al.
and provides additional metabolic validation of PfHGXPRT
as an in vitro antimalarial target.
EXPERIMENTAL PROCEDURES
Gene Construction and Protein Purification
Codon-optimized genes were obtained from DNA 2.0 (Menlo Park, CA) using
the amino acid sequence from PfHGXPRT (Gene ID: PF10_0121, http://
plasmodb.org/plasmo) and the human HGPRT crystal structure (Protein
Data Bank ID: 1BZY). An N-terminal thrombin cleavable 6-His tag
(MGSSHHHHHHSSGLVPNGSH) was added to aid in purification. The gene
was inserted in pDONR221 (Invitrogen). Both plasmids were overexpressed
in BL21AI cells and enzymes were purified by methods described previously
(Taylor et al., 2007b). PfHGXPRT was dialysed against 50 mM potassium
phosphate (pH 7.5), 150 mM KCl, 5 mM imidazole, 1 mM DTT, and 10%
glycerol and human HGPRT against 10 mM Tris (pH 7.5), 150 mM KCl,
5 mM imidazole, 1 mM DTT, and 10% glycerol. The enzymes were then
concentrated to 15 mg ml1 and frozen drop-wise in liquid nitrogen. PNP
was purified as previously described (Taylor et al., 2007a).
Inhibitors and Prodrugs
Compounds 1–8were synthesized at Industrial Research Limited, Lower Hutt,
New Zealand and detailed synthetic procedures will be published separately.
Inhibition Assays
PfHGXPRT activity was measured using spectrophotometric assays
observing the conversion of xanthine and 5-phospho-a-D-ribose-1-pyrophos-
phate to xanthosine-50-monophosphate and inorganic pyrophosphate (PPi) at
247 nm ( 3257 – 6.8 mM
1 cm1) or the conversion of guanine and PRPP to
guanosine-50-monophosphate and PPi ( 3257 – 5.8 mM
1 cm1) on a Varian
Cary 100 spectrophotometer (Palo Alto, CA) at 37C. All assays were con-
ducted in 10 mM potassium phosphate (pH 7.6), 10 mM MgCl2, 1 mM
PRPP, 150 mM xanthine or 50 mM guanine, 0.5 mM DTT with varying amounts
of inhibitor and concentrations of PfHGXPRT between 2 and 10 nM or human
HGPRT of 1 nM. As the dissociation constants of many of the inhibitors were
near or below that of the enzyme concentration, the data were fit to the721–730, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 727
Figure 6. The Active Site of PfHGXPRT
Bound to AIP-3 and MgPPi
Hydrogen bonds are represented as dashed lines.
(A) The purine binding site.
(B) The pyrophosphate and ribose binding sites
with the ionic bonds coordinating magnesium
represented as green dashed lines.
(C) The 50-phosphate binding site.
(D) Comparison of the purine nucleobase positions
of ImmHP and 3 illustrating the 11 tilt of nucleo-
base 3 compared to ImmHP.
(E) Two-dimensional representation of the active
site where the ionic bond between pyrophosphate
and the ribocation mimic is represented as a thick
dashed line. Water molecules are represented as
red dots and the hydrophobic residues interacting
with the purine ring are drawn in orange.
See also Figure S2.
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Inhibitors of Human and Malarial HGPRTsMorrison equation for tight-binding inhibitors (Morrison, 1969). PNP inhibition
assays were carried out as previously described (Clinch et al., 2009).
Crystallization, Data Collection, and Structural Determination
PfHGXPRTwas concentrated to 12–20mgml1 anddialyzedwith either 50mM
phosphatebuffer (pH7.4) or 50mMNaCl and10mMTris buffer (pH7.4). Prior to
protein crystallization, PfHGXPRT was incubated on ice with 1 mM hypoxan-
thine, 2 mM PPi and 5 mMMgCl2 or 1 mM 3, 2 mM PPi, and 2 mMMgCl2. The
hypoxanthine-bound PfHGXPRT was crystallized in 20% PEG3350, 0.2 M
sodium citrate and the complex of PfHGXPRT with 3 was crystallized in728 Chemistry & Biology 19, 721–730, June 22, 2012 ª2012 Elsevier Ltd All rights reserved20% PEG3350, 0.2 M ammonium citrate (pH 7.0)
using the sitting drop vapor diffusion method at
18C. Crystals were briefly transferred to the
reservoir solution supplementedwith 20%glycerol
and frozen in liquid N2 before data collection.
X-ray diffraction data were collected at beam-
line X29A of Brookhaven National Laboratory on
an ADSC Q315 detector at 100 K. Data were pro-
cessed with the HKL2000 program suite and data
processing statistics are provided in Table 2 (Otwi-
nowski and Minor, 1997).
The crystal structures of liganded PfHGXPRT
were determined by molecular replacement in
Molrep using the published structure of
PfHGXPRT from which ImmHP, PPi, Mg
2+ ion
and water molecules were removed as the search
model (PDB ID: 1CBJ) (Collaborative Computa-
tional Project, Number 4, 1994). Themodel without
ligands was first rebuilt in COOT and refined in
Refmac5 (Emsley and Cowtan, 2004; Potterton
et al., 2003). The ligands were later included in
COOT using the Fo - Fc map when the Rfree was
below 30% and further refined in Refmac5. A
phosphate ion was found in the active site of
PfHGXPRT in complex with hypoxanthine and
magnesium pyrophosphate based on the strong
positive peak in the Fo - Fc electron density map.
The final model was validated by Molprobity. The
refinement statistics are summarized in Table 2.
The coordinates and structure factors for the
hypoxanthine- and C-complexes of PfHGXPRT
were deposited in the Protein Data Bank under
accession codes 3OZG and 3OZF, respectively.
Cell Culture Inhibition Assay
Activity of compounds were tested as previously
described (Cassera et al., 2008). Compounds 5and 6 were dissolved in sterile water by sonication in a warm water bath;
compound 7was dissolved in DMSO; compound 8was poorly soluble in water
or DMSO. Compound 8was dissolved in sterile water, added tomalaria culture
media and concentrated by lyphophilization.
Metabolic Labeling
Erythrocytes, infected erythrocytes and erythrocyte-free parasites in the
trophozoite stage were treated with 25 mM 1, 100 mM 4, 10 mM 5 and 6,
or 15 mM 8 for 1 hr at 37C. Cells were then labeled with 1 mM [2,8-3H]hypoxan-
thine (30 Ci/mmol, Moravek) or 1 mM [2,8-3H]inosine (50 Ci/mmol, Moravek) for
Table 2. Crystallographic Data Collection and Refinement
Statistics
Hypoxanthine 3
PDB codes 3OZF 3OZG
Data collection
Space group P21 C2221
Cell dimension
a, b, c (A˚) 75.0, 88.9, 80.4 105.1, 110.6, 173.3
a, b, g () 90.0, 117.1, 120.0 90.0, 90.0, 90.0
Resolutions (A˚) 50.00–1.95
(2.02–1.95)
20.00–2.00
(2.07–2.00)
Rsym (%) 9.3 (41.3) 14.9 (70.7)
I / sI 15.1 (3.8) 12.5 (1.8)
Completeness (%) 99.9 (99.9) 98.5 (88.7)
Redundancy 4.9 (4.5) 7.3 (5.6)
Refinement
Resolution (A˚) 50.00–1.95 20.00–2.00
No. unique reflections 68,875 67,383
Rwork / Rfree (%) 18.9/23.7 21.9/26.4
B factors (A˚2)
Protein
(Main chain) 19.3 28.0
(Side chain) 22.1 29.5
Water 25.3 28.1
Ligand 20.0 24.7
No. of atoms
Protein 7,444 7,390
Water 409 212
Ligand 102 124
Rmsd
Bond lengths (A˚) 0.015 0.012
Bond angles () 1.53 1.50
Ramachandran analysis
Favored region 95.8% 96.0%
Allowed region 4.2% 4.0%
Disallowed region 0% 0%
Coordinate error by
Luzzati plot (A˚)
0.21 0.28
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Inhibitors of Human and Malarial HGPRTs1 hr at 37C. Parasites from infected erythrocytes were isolated by lysis with
0.045% saponin either before addition of radiolabel or after incubation with
radiolabel. Proteins and nucleic acids were removed by perchloric acid treat-
ment of supernatants and cell pellets (Cassera et al., 2008). All samples were
analyzed by high-pressure liquid chromatography (HPLC) with a modification
in the previously described solvent gradient (Cassera et al., 2008). Briefly, the
mobile phases were 8 mM tetrabutylammonium bisulfate (Fluka) and 100 mM
KH2PO4 with the pH adjusted to 6.0 with KOH in water (solution A) or 30%
acetonitrile (solution B). The HPLC gradient was from 0% to 10% solution B
in 4 min and maintained for 2 min, 10% to 20% solution B in 1 min, 20% to
40% solution B in 10 min, 40% to 100% solution B in 3 min and maintained
for 4 min.
UPLC/MS/MS
Samples were placed in 96-deep-well plates, treated with 0.5 M HClO4 at 1:7
(v/v, sample/HClO4), incubated for 20min at 4
C and neutralized with 5MKOH
at 10:1 (v/v, HClO4/KOH) for 20 min at 4
C. Plates were centrifuged (10 minChemistry & Biology 19,at 4,000 rpm, 4C) and supernatants were filtered through a MultiScreen Filter
Plate with Ultracel-10 Membrane (Millipore). Metabolite and inhibitor levels
were analyzed by UPLC/MS/MS using a Xevo TQD mass spectrometer
(Waters). The separation of inosine, hypoxanthine, and inhibitors was achieved
with an Acquity HSS T3 column (2.1 3 100 mm, 1.8 mm, Waters) at 60C. The
eluent system was composed of 5 mM ammonium formate in water (A) and
5 mM ammonium formate in methanol (B) with a gradient of 98% eluent
A to 30% eluent B from 0.1 to 1 min, 70% eluent A to 80% eluent B from
1 to 1.5 min and back to 98% eluent A from 1.5 to 3 min at a flow rate
of 0.6 ml min1. Detection was performed in electrospray ionization (ESI)
positive-ion mode using multiple-reaction monitoring mode. For ESI-MS/MS
analysis, the following ion transitions, cone voltage (CV) and collision
energy (CE) were used: inosine m/z 269.1 > 137.1 (CV: 14 V, CE: 12 eV),
hypoxanthine m/z 137.1 > 110.0 (CV: 42 V, CE: 18 eV), compound 1 m/z
659.06 > 212.90 (CV: 34 V, CE: 40 eV), compound 2 m/z 286.92 > 139.74
(CV: 22 V, CE: 14 eV), compound 4 m/z 515.05 > 205.76 (CV: 34 V, CE:
28 eV). The ESI capillary voltage was 0.3 kV, source temperature was set at
150C and desolvation temperature at 450C. Data acquisition and analysis
were carried out by MassLynx V4.1 and QuanLynx software.
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